To the full analysis
Ardent Health stock: growth
ARDTArdent Health reported $6.32B in revenue for fiscal 2025, up 6% on the prior year, up 8.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
15.3%
per year from 2015 to 2025, per share 15.3%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
26.6%
per year from 2015 to 2025, per share 26.6%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2018 | since 2015 | |
|---|---|---|
| Revenue | 8.7% | 15.3% |
| Revenue per share | 8.8% | 15.3% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | 26.6% |
| Free cash flow per share | no data | 26.6% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2015 | $2.03B | −$46.36M | $39.31M |
| 2016 | $2.11B | $14.6M | $5.27M |
| 2017 | $3B | −$35.65M | −$2.06M |
| 2018 | $4.16B | −$143.02M | −$1.07M |
| 2021 | $4.87B | $154.26M | $7.91M |
| 2022 | $5.13B | $188.91M | −$189.47M |
| 2023 | $5.41B | $50.29M | $84.29M |
| 2024 | $5.97B | $210.34M | $127.52M |
| 2025 | $6.32B | $135.81M | $258.61M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 8 Aug 2025)
- Valuation signal Fairly valued since 7 Nov 2026, previously Undervalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.